Telomir Pharmaceuticals Announces Osteosarcoma Research Findings

What Happened
On September 14, 2026, Telomir Pharmaceuticals, Inc. announced new preclinical results from The Ohio State University College of Veterinary Medicine showing its Telomir‑Zn candidate produced dose‑dependent inhibition of cell growth across three osteosarcoma cell lines (human HOS; canine D17 and Abrams). The company said all three lines showed growth inhibition at similar low drug concentrations. Telomir reiterated that its immediate clinical focus remains the Telomir‑Zn program in advanced/metastatic triple‑negative breast cancer (TNBC), which is progressing toward site initiation and Phase 1/2 patient enrollment under an active Investigational New Drug (IND) cleared by the FDA.

Key Details

• Date filed: September 14, 2026 (8‑K disclosure of press release).
• Models tested: HOS (human), D17 (canine), Abrams (canine).
• Result: Dose‑dependent anti‑tumor activity with growth inhibition in all three lines at similar low concentrations.
• Next steps: Telomir is discussing a possible in vivo efficacy study in canine osteosarcoma with Ohio State; this could support a veterinary indication and provide translational insight for human studies.

Why It Matters
The data represent early preclinical evidence that Telomir‑Zn may have activity beyond the company’s lead clinical focus (TNBC). A veterinary pathway (canine osteosarcoma) could provide faster in vivo data and a potential separate development/market opportunity, while ongoing IND‑enabled clinical work in TNBC advances. Investors should note these are preclinical cell‑line results; no clinical osteosarcoma data, financial terms, timelines or regulatory filings for a veterinary program were disclosed in the 8‑K.